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Targeting angiogenesis for fracture nonunion treatment in
inﬂammatory disease
Cuicui Wang1, Jun Ying1,2,3, Xiaolei Nie4, Tianhong Zhou4, Ding Xiao1, Gaurav Swarnkar1, Yousef Abu-Amer
Jie Shen1

1,5

, Jianjun Guan4 and

1234567890();,:

Atrophic fracture nonunion poses a signiﬁcant clinical problem with limited therapeutic interventions. In this study, we developed a
unique nonunion model with high clinical relevance using serum transfer-induced rheumatoid arthritis (RA). Arthritic mice
displayed fracture nonunion with the absence of fracture callus, diminished angiogenesis and ﬁbrotic scar tissue formation leading
to the failure of biomechanical properties, representing the major manifestations of atrophic nonunion in the clinic. Mechanistically,
we demonstrated that the angiogenesis defect observed in RA mice was due to the downregulation of SPP1 and CXCL12 in
chondrocytes, as evidenced by the restoration of angiogenesis upon SPP1 and CXCL12 treatment in vitro. In this regard, we
developed a biodegradable scaffold loaded with SPP1 and CXCL12, which displayed a beneﬁcial effect on angiogenesis and
fracture repair in mice despite the presence of inﬂammation. Hence, these ﬁndings strongly suggest that the sustained release of
SPP1 and CXCL12 represents an effective therapeutic approach to treat impaired angiogenesis and fracture nonunion under
inﬂammatory conditions.
Bone Research (2021)9:29
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INTRODUCTION
Approximately ten percent of the 16 million fractures that occur
annually in the United States do not progress to timely union and
exhibit prolonged healing or nonunion.1,2 There are two distinct
types of fracture nonunion characterized by different radiographical observations and biological properties, atrophic and
hypertrophic nonunion.3 The development of hypertrophic
nonunion is primarily due to inadequate mechanical stability
that leads to excessive fracture callus formation; therefore,
appropriate mobilization and ﬁxation at the fracture site are
usually used in the clinic to achieve a successful outcome in
hypertrophic nonunion patients.4 In contrast, atrophic nonunion
is characterized by limited fracture callus with poor tissue
revascularization, likely secondary to the perturbation of normal
biological cues. Treatment of atrophic nonunion usually involves
complex clinical intervention practices and often requires multiple surgeries. Thus, atrophic nonunion results in signiﬁcant
patient disability and increased cost to the health care system.5
While bone graft surgeries, mechanical stimulation devices, and
therapies using growth factors and stem cells have been
developed, the effective management of atrophic nonunion is
limited, and atrophic nonunion remains a major clinical challenge
for orthopedic surgeons.
A major population affected by atrophic nonunion is patients
with inﬂammatory conditions, e.g., elderly patients, individuals
who smoke, and diabetic or rheumatoid arthritis (RA) patients.6–8
In these patients, the fracture risk is increased due to poor bone

quality,7,9–12 highlighting the potential deleterious role of chronic
systemic inﬂammation in fracture repair. This can be observed in
preclinical models. Indeed, TNFα-transgenic mice showed
impaired bone quality, including reduced cortical thickness,
leading to decreased fracture toughness.13 In addition, experiments using a mouse cortical defect model showed that bone
regeneration was also signiﬁcantly reduced in RA mice.14 Studies
from patients and rodents have extensively reported that chronic
systemic inﬂammation activates the canonical NF-κB pathway,
resulting in the elevated expression of IL-1β, TNFα, and other
cytokines,12,15–18 impairing the fracture repair process at least
partially by negatively affecting angiogenesis.19–22 Although
pharmacological anticytokine therapies have been developed
and are highly effective in RA patients,23–26 the impact of these
agents on fracture healing in patients with inﬂammatory arthritis
is not known. Preclinical animal studies showed that the TNFα
inhibitor inﬂiximab had a positive effect on the restoration of
callus formation and biomechanical properties of fractured bone
in wild-type rats under chronic inﬂammatory conditions.27 In
contrast, a human cohort study in ankylosing spondylitis patients
demonstrated the negative long-term effect of TNFα inhibitor
treatment on fracture healing.28 Therefore, there is an urgent need
to develop molecular therapies for fracture nonunion, especially
for older patients with chronic inﬂammatory diseases. In this
study, we show that serum transfer-induced RA (also known as K/
BxN) mice develop atrophic nonunion, with the absence of
fracture callus, and coincident diminished angiogenesis. Despite
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the large amount of evidence on the role of the NF-κB pathway in
fracture studies, the mechanisms by which pathologic inﬂammation adversely affects angiogenesis during fracture healing are
largely unknown. Here, we used this novel RA nonunion model to
study the cellular and molecular basis of the negative impact of
inﬂammation on angiogenesis.
During normal fracture repair, chondrocytes and osteoblasts are
the primary cell types that secrete angiogenic factors, recruiting
endothelial cells and facilitating angiogenesis and vasculogenesis.29–33 As a key initial step, the re-established vascular network
brings oxygen and nutrients to facilitate bone regeneration in
addition to osteoprogenitors, osteoblasts and other cells, which are
necessary for callus maturation and bone formation. However,
under inﬂammatory conditions, insufﬁcient revascularization34,35
occurs, particularly leading to atrophic nonunion.36–40 Through an
unbiased in vitro screen of angiogenic factors, we found that
secreted phosphoprotein 1 (SPP1) and C-X-C motif chemokine
ligand 12 (CXCL12) are the two factors downregulated to the
greatest extent by IL-1β treatment, suggesting SPP1 and CXCL12 as
potential targets of inﬂammation in chondrocytes. Both SPP141–44
and CXCL1245–48 are highly expressed in chondrocytes and
osteoblasts during fracture repair, and recent rodent studies
suggest that SPP1 and CXCL12 contribute to fracture healing
through the improvement of neovascularization.49,50 To target the
angiogenesis process, we developed biodegradable scaffolds
capable of continuously releasing SPP1 and CXCL12 locally at the
fracture site. Strikingly, the sustained delivery of SPP1 and CXCL12
accelerated fracture union in RA mice and restored biomechanical
properties, highlighting this approach as a potential therapeutic
strategy to treat atrophic fracture nonunion in patients with
inﬂammatory diseases.
RESULTS
Elevated inﬂammation led to fracture nonunion in RA mice
The rising global prevalence of inﬂammatory diseases, especially
RA,51–53 is associated with debilitating comorbidities and clinical
complications, including delayed fracture union and nonunion.8,54,55 To examine the effect of inﬂammation/RA on fracture
repair, we generated RA mice via repeated intraperitoneal (i.p.) K/
BxN serum administration every 5 days to maintain systemic
inﬂammation. Given that the transcription factor NF-κB is the
principal mediator and agent of inﬂammatory responses, we
examined its activity using NF-κB/RelA-Luc reporter mice subjected to RA conditions. Consistent with the expected increase in
inﬂammation, we conﬁrmed that the RA mice displayed signiﬁcantly higher luciferase activity, especially in the limbs,
compared to that in the control group (Fig. S1A). Importantly,
inﬂammation was elevated, peaking at 10 days after serum
administration, and this increase was maintained for at least
15 days (Fig. S1B). Clinical reports and rodent studies have shown
that elevated inﬂammatory cytokines are the major factors that
contribute to RA-related comorbidities. Indeed, we showed that
mRNA expression levels of the inﬂammatory cytokines Il1β, Il6,
Il10, and Tnfα were signiﬁcantly elevated in the fracture calluses of
the RA mice (Fig. S2). Importantly, compared to the control mice,
the RA mice developed impaired fracture repair with diminished
cartilaginous and bony callus formation, as reﬂected by histological analyses at 10 and 14 days post fracture (dpf) tibiae (Fig. 1a).
Consistent with the histology results, quantitative histomorphometry conﬁrmed a minimal cartilage template and newly formed
woven bone in the RA callus at 10 and 14 dpf (Fig. 1b, c). We then
performed microCT to further examine the mineralized callus in
the control and RA mice. We found a gradual increase in new
bone formation around the fracture area by 14 dpf in the control
mice. The fracture gap in the control mice had closed at 21 dpf,
with robust bone formation and complete healing. In contrast, the
fracture gap in the RA mice persisted until 21 dpf, as shown by

microCT, with signiﬁcantly reduced newly formed bone tissue and
bone volume over total volume (BV/TV) ratio (Figs. 1d, e; S3).
Notably, collagen III-positive ﬁbrotic tissue was present in the
center of the RA fracture callus instead of woven bone tissue in
the control fracture, suggesting an atrophic nonunion fracture in
the RA mice (Fig. 1f). Finally, we performed torsion testing to
evaluate the mechanical properties of the tibia at 28 dpf as the
ultimate indicator of fracture repair outcome in the control and RA
mice. Compared to the fractured tibiae of control mice, the
fractured tibiae of RA mice displayed signiﬁcantly lower maximum
torque (77% reduction) with a larger displacement angle,
indicating poor bone strength and rigidity of newly formed bone
in the RA mice (Fig. 1g). Altogether, these data conﬁrmed that
under RA conditions, mice displayed systemic inﬂammation
mediated by cytokines and developed fracture nonunion.
Inﬂammation reduced the expression of angiogenic factors and
impaired angiogenesis in mice
Clinical studies and rodent models have established that defects
in vascularization coincide with fracture nonunion, especially
under inﬂammatory conditions, such as those in RA. Consistent
with these reports, we observed that the control mice formed
blood vessels at 10 dpf, the peak angiogenic time point in murine
fracture healing. In contrast, callus tissues from the RA mice
showed diminished angiogenesis and poor angiogenic connectivity at 10 dpf (Fig. 2a). Quantiﬁcation conﬁrmed signiﬁcantly
fewer blood vessels in the fractured calluses of RA mice at 10 dpf
(Fig. 2b). We also performed immunohistochemistry (IHC) to
detect endomucin-positive blood vessels in the fractured calluses.
Similar to the angiography results, IHC revealed almost nondetectable blood vessels in the fractured calluses of RA mice, but
abundant blood vessels were observed in the fractured calluses of
control mice at 10 dpf (Fig. 2c, d). These data indicate that
systemic inﬂammation had adverse effects on the expression of
angiogenic factors, leading to reduced angiogenesis during
fracture repair. Since chondrocytes and osteoblasts31–33,56–59
are the primary cell types that secrete angiogenic factors in the
fracture callus to stimulate blood vessel formation,36,60,61 we
isolated primary chondrocytes and osteoblasts and treated them
with IL-1β in vitro for 72 h to examine the effect of inﬂammation
on the production of angiogenic factors by these cells. A protein
array (53 angiogenic factors) was used to determine the presence
of angiogenic mediators in the culture supernatant from
chondrocytes and osteoblasts. Interestingly, we noticed that
inﬂammation signiﬁcantly reduced expression of the angiogenic
factors SPP1, CXCL12, C-X-C motif chemokine ligand 1 (CXCL1),
and C-C motif chemokine ligand 2 in chondrocytes but induced
the expression of C-X-C motif chemokine ligand 4 (CXCL4), C-X-C
motif chemokine ligand 10 (CXCL10) and vascular endothelial
growth factor (VEGF) (Fig. 2e, f). Surprisingly, the expression of
angiogenic factors in osteoblasts was minimally altered by IL-1β
treatment (Fig. S4A). Even the expression of SPP1, VEGF, plateletderived growth factor, and placental growth factor 2 was
signiﬁcantly increased under IL-1β treatment in primary osteoblasts (Fig. S4B). These data highlight the key role of chondrocytes
in the angiogenesis defects observed in the RA mice during
fracture nonunion. Since other inﬂammatory cytokines, such as IL6 and TNFα, were shown to be upregulated in the fractured callus
in RA (Fig. S2), we also treated primary chondrocytes with IL-6 and
TNFα. Similar to the effect of IL-1β, treatment with IL-6 and TNFα
also reduced the protein expression of SPP1 and CXCL12 in
chondrocytes (Fig. S5).
SPP1 and CXCL12 restored angiogenesis in inﬂammation in vitro
Since SPP1, the most abundantly expressed factor in chondrocytes,
was the factor most signiﬁcantly reduced by IL-1β and CXCL12, we
then focused on these two angiogenic factors and examined
whether SPP1 and CXCL12 are the downstream targets of
Bone Research (2021)9:29

The role of angiogenesis in fracture nonunion
C Wang et al.

3
RA

10 dpf

1.5

1.5

Relative cartilage area

Ctrl

b

Relative bone area

a

1.0

0.5

*
0.0

*

RA

Ctrl

RA

1.5

Relative bone area

14 dpf

0.5

0.0
Ctrl

c

1.0

1.0

0.5

*
0.0
Ctrl

d

Ctrl

RA

e

RA

1.5

1.0

0.5

*

Relative BV/TV

21 dpf

Relative bone volume

1.5

0.0

PBS

*

0.5

0.0
Ctrl

f

1.0

RA

Ctrl

RA

RA

Max torque/(N·mm)

20
15
10

*

5
0
Ctrl

RA

Displacement at max/degree

g
150

*

100

50

0
Ctrl

RA

Fig. 1 Systemic inﬂammation-induced fracture nonunion in RA mice. a Representative ABH/OG staining of fracture callus sections from
control and RA mice at 10 and 14 dpf (n = 5). Histomorphometric quantiﬁcation of cartilage and bone area was performed on (b) 10 dpf and
(c) 14 dpf fracture callus sections from the control and RA mice (n = 5). The results were normalized to the controls. *P < 0.05 compared with
control by Student’s t test. d MicroCT assessment of mineralized bone within the fracture callus at 21 dpf from the control and RA mice (n = 5).
e Quantiﬁcation of bony callus volume and relative BV/TV ratio based on microCT assessment of 21 dpf control and RA fracture calluses. All
results were normalized to controls. *P < 0.05 compared with control by Student’s t test. f Immunohistochemical staining of 21 dpf fracture
calluses from control and RA mice for COL3A1. g Biomechanical torsion testing of the control and RA fractures at 28 dpf (n = 5). Max torque
and displacement at max were quantiﬁed. All results were normalized to the controls. *P < 0.05 compared with control by Student’s t-test.
Scale bar, 200 μm

inﬂammation that mediate angiogenic defects. On the one hand,
we conﬁrmed that, consistent with the protein expression, Spp1 and
Cxcl12 gene expression was also decreased in the fractured calluses
of RA mice at 10 dpf compared to those of control mice (Fig. 3a).
Furthermore, IHC analysis of fractured tissue at 10 dpf revealed
abundant expression of SPP1 and CXCL12 in the fractured calluses
Bone Research (2021)9:29

of control mice but almost nondetectable expression of SPP1 and
CXCL12 in the fractured calluses of RA mice (Fig. 3b), conﬁrming the
downregulation of SPP1 and CXCL12 mediated by inﬂammation in
the context of fracture repair under RA conditions. To conﬁrm the
physiological effect of inﬂammation on chondrocyte-mediated
regulation of angiogenesis, we examined the in vitro angiogenesis
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Fig. 2 Systemic inﬂammation led to impaired angiogenesis. a MicroCT assessment of newly formed vessels within 10 dpf fracture calluses
from control and RA mice. b Quantiﬁcation of vessel counts in 10 dpf control and RA fracture calluses (n = 5) based on microCT assessment.
The results were normalized to the controls. *P < 0.05 compared with control by Student’s t test. c Immunohistochemical staining for
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by Student’s t test. e Representative images of an angiogenesis proteasome array from the culture medium of chondrocytes following vehicle
and IL-1β treatment. f Quantiﬁcation of blot intensity from the angiogenesis proteasome array (n = 4). All results were normalized to the
controls. *P < 0.05 compared with control by Student’s t test. Scale bar, 200 μm

of human umbilical vein endothelial cells (HUVECs) using culture
medium supernatants collected from primary chondrocytes treated
with vehicle or IL-1β (Fig. 3c–e). Consistent with our in vivo ﬁndings
on angiogenesis, the control culture supernatants from vehicletreated chondrocytes exhibited robust cell migration as well as an
abundance of well-developed vessel tubes in vitro. In contrast,
signiﬁcant reductions in HUVEC migration, tube number, and tube
length were observed in the presence of culture supernatant from
IL-1β-treated chondrocytes. This was not related to the continued
presence of IL-1β in the supernatant, since our angiogenic factor
protein array conﬁrmed that there was no IL-1β left in the culture
medium after 72 h of IL-1β treatment (Fig. 2e). In addition,
compared to culture medium from vehicle-treated chondrocytes,
culture medium from IL-1β-treated chondrocytes did not clearly
alter HUVEC proliferation or apoptosis (Fig. S6), suggesting that the
decreased angiogenic capacity of the culture medium was at least
partially attributed to reduced SPP1 and CXCL12 but not
dysfunction of the HUVECs themselves. Therefore, based on our
previous studies, we applied 500 ng·mL−1 SPP1 and 100 ng·mL−1

CXCL12 to the chondrocyte culture medium and performed HUVEC
angiogenesis assays. As expected, the administration of SPP1 and
CXCL12 individually or in combination to the culture medium from
vehicle-treated chondrocytes resulted in the induction of HUVEC
migration and tube formation. More importantly, exogenous SPP1
and CXCL12 administration restored angiogenic capacity, as
reﬂected by increased cell migration, tube number, and tube
length with culture medium from IL-1β-treated chondrocytes. We
also noticed that the combined administration of SPP1 and CXCL12
had the most profound restorative effect on in vitro HUVEC
angiogenesis. These data, together with the murine RA fracture
nonunion model, identify reductions in SPP1 and CXCL12 as the
molecular basis for the negative impact of inﬂammation on
angiogenesis and present SPP1 and CXCL12 as potential therapeutic approaches to treat fracture nonunion.
Delivery of SPP1 and CXCL12 via a biodegradable scaffold
To promote angiogenesis at fracture sites while avoiding excessive
angiogenesis in other tissues, we designed a scaffold made of
Bone Research (2021)9:29
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polycaprolactone (PCL), a US Food and Drug Administration (FDA)approved biodegradable polymer for tissue engineering applications, to deliver SPP1 and CXCL12 locally.62 We used our unique
electrospinning and electrospraying system63 to fabricate PCL
Bone Research (2021)9:29

scaffolds, i.e., by simultaneously electrospinning PCL ﬁbers and
electrospraying poly(lactide-co-glycolide) (PLGA) microspheres
loaded with SPP1 (100 μg·mL−1) and/or CXCL12 (20 μg·mL−1)
(Fig. 4a). To demonstrate the core–shell structured microspheres,
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we mixed a PLGA solution with rhodamine B and simultaneously
mixed growth factor solution with Hoechst. The ﬂuorescent
images shown in Fig. 4b conﬁrmed that the microspheres
assumed a core–shell structure with PLGA as the shell and SPP1
or CXCL12 as the core (Fig. 4b). The scaffold structure and
microsphere distribution were characterized by scanning electron
microscopy (SEM). The PCL scaffold was formed by interlaced
ﬁbers, and microspheres with a diameter of ~5 μm were
distributed uniformly in the scaffolds (Fig. 4c). The scaffolds were
strong, with a tensile strength of 28.8 MPa and Young’s modulus
of 111.5 MPa (Fig. S7). Finally, we examined the release proﬁles of
SPP1 and CXCL12 in vitro over a 4-week period. According to the
ELISAs of the collected medium, SPP1 and CXCL12 exhibited a
two-stage release pattern (Fig. 4d). Both displayed burst release in
the ﬁrst 3 days, followed by controlled slow release until day 28.
Furthermore, the release of SPP1 and CXCL12 from the scaffold
loaded with both SPP1 and CXCL12 was slower than that from the
scaffold loaded with each individual growth factor (Fig. 4d).
Release of SPP1 and CXCL12 promotes angiogenesis under
inﬂammatory conditions
Since the RA mice displayed a systemic inﬂammatory environment, particularly the increased expression of inﬂammatory

cytokines identiﬁed in the fracture sites (Fig. S2), we examined
whether the SPP1 and CXCL12 released from the scaffolds could
promote HUVEC angiogenic capacity under inﬂammatory conditions. We mimicked the scenario in which the scaffold is implanted
at the fracture site. We placed collagen gel on top of PCL scaffolds
loaded with SPP1 and/or CXCL12 and then cultured CM-Dil dyelabeled HUVECs on the collagen gel under control or inﬂammatory
conditions (Fig. 5a). The migration of HUVECs on the collagen gel
was then examined by confocal microscopy. As expected, IL-1β
treatment signiﬁcantly reduced HUVEC migration, particularly in
the deep zone from 50 to 110 μm from the top surface (Fig. 5b).
However, growth factors substantially promoted migration under
IL-1β treatment (Fig. 5b). The SPP1 released from the scaffold
loaded with SPP1 alone promoted HUVEC migration to a greater
extent than the CXCL12 released from the scaffold loaded with
CXCL12 alone. The greatest cell migration was found in the group
with both SPP1 and CXCL12 release, especially in the deep zone
up to 110 μm from the top surface (Fig. 5b). In addition to cell
migration, we examined tube formation based on lumens formed
in the collagen gel, with a particular focus on the area containing
the majority of the HUVECs. IL-1β treatment signiﬁcantly reduced
tube formation, as reﬂected by decreased lumen formation in the
collagen gel in the top surface (10 μm) and deep zone (50 μm),
Bone Research (2021)9:29
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Fig. 5 The release of SPP1 and CXCL12 promoted angiogenesis under inﬂammatory conditions. a Schematic illustration of the collagen
construct that was used to create the 3D cell culture environment to examine the impact of released growth factors on HUVEC migration and
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lumen density at different depths in the collagen gel (n = 5). *P < 0.05 compared with control by two-way ANOVA. Scale bar, 200 μm

although no difference in HUVEC migration was observed on the
surface under IL-1β treatment. Importantly, lumen formation was
restored in the groups in which scaffolds were loaded with SPP1
and CXCL12, even under inﬂammatory conditions. The lumen
density in the group with only CXCL12 release was signiﬁcantly
higher than that in the group with only SPP1 release. The group
Bone Research (2021)9:29

with both SPP1 and CXCL12 release had a signiﬁcantly greater
lumen density than the group with CXCL12 release alone both on
the surface and in the deep zone (Fig. 5c, d). Altogether, these
data conﬁrmed that SPP1 and CXCL12 were gradually released
over 4 weeks from the scaffolds, which could potentially beneﬁt
angiogenesis and inﬂammatory bone fracture healing.
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Controlled release of SPP1 and CXCL12 restored angiogenesis and
fracture union in RA mice
With the observation of the bioactivity of PCL scaffolds in vitro,
we applied the scaffolds with SPP1 (100 μg·mL−1) and/or CXCL12
(20 μg·mL−1) to treat fracture nonunion in RA mice. A 2-mm
scaffold was wrapped around the fractured bone immediately
after the fracture procedure (Fig. 6a). Vascular structure and the
fracture healing process were evaluated 10 days after the
application of scaffolds by microCT and histology, respectively.
Similar to RA mice, diminished angiogenesis was observed at
10 dpf in callus tissue treated with the PCL scaffold without
growth factors under systemic inﬂammation in vivo. In contrast,
the PCL scaffold with SPP1 and/or CXCL12 induced a signiﬁcant
angiogenic response in calluses at 10 dpf, resulting in the
formation of more blood vessels under RA conditions (Fig. S8A, B
and Fig. 6b, c). Consistent with the observation of in vitro
angiogenesis assays, SPP1 and CXCL12 in combination achieved
the greatest restorative effect on blood vessel formation in RA
mice compared to the individual SPP1 and CXCL12 treatments.
We also performed IHC to detect endomucin-positive blood
vessels in fracture calluses at 10 dpf and revealed signiﬁcantly
more blood vessels in the fracture calluses of RA mice to which
the PCL scaffold containing both SPP1 and CXCL12 was applied
(Fig. 6d, e). More importantly, coincident with the restoration of
blood vessels in the fracture callus, newly formed woven bone
was also observed in RA mice treated with SPP1 and CXCL12 via
the PCL scaffold. Individual SPP1 and CXCL12 treatment similarly
increased the amount of woven bone (eightfold increase) in
the region adjacent to the fracture at 10 dpf (Fig. S8C, D). The
application of SPP1 and CXCL12 together increased woven bone
in calluses at 10 dpf by 25-fold. Notably, the newly formed bone
replaced the ﬁbrotic tissue and uniﬁed the fracture nonunion in
the RA mice after 10 days of local treatment with SPP1 and
CXCL12 (Fig. 6f, g). Finally, we measured the bone biomechanical
properties by the torsion test and found that the maximum bone
strength in the RA mice treated with SPP1 and CXCL12 was
signiﬁcantly restored by 28 dpf (Fig. 6h). Hence, these ﬁndings
strongly suggest that the local release of SPP1 and CXCL12 via
PCL scaffolds represents an effective therapeutic approach to
treat impaired angiogenesis and fracture nonunion under
inﬂammatory conditions.
DISCUSSION
Despite the growing knowledge of atrophic nonunion from animal
models, fracture nonunion remains an exceedingly challenging
clinical problem with limited and mainly invasive therapeutic
interventions. To date, the atrophic nonunion models64 available
for mechanistic and therapeutic studies primarily rely on critical
size bone defects and removal of the periosteum,65 which are
particularly valuable to delineate the effect of periosteum tissue
and progenitor cell differentiation on disease initiation and
progression. Nevertheless, these animal models lack clinical
relevance and rarely reﬂect the clinical scenario, since atrophic
nonunion is more prevalent in patients under chronic inﬂammatory conditions, including those in diabetes and RA. In this study,
we have demonstrated for the ﬁrst time that RA mice developed
atrophic nonunion under chronic inﬂammation induced by K/BxN
serum. Speciﬁcally, the use of NF-κB reporter mice conﬁrmed that
elevated inﬂammation was observed in the RA mice, particularly in
the hinder limbs, and maintained for at least 15 d. The expression
of inﬂammatory factors was also induced locally in the fracture
calluses of RA mice. Furthermore, the RA mice displayed (a) no
fracture callus formation, (b) ﬁbrotic scar tissue within the fracture,
(c) diminished angiogenesis, and (d) poor mechanical performance,
all of which are consistent with the clinical manifestations of
atrophic nonunion in patients. Thus, this work highlights a novel
RA nonunion model with high clinical relevance and provides a

useful tool to study the pathology of atrophic nonunion under
inﬂammation.
Although bone healing failure is due to interplay between
multiple components, including defects of growth factors,
progenitor cells and mechanical factors, a lack of blood supply
has long been believed to be an essential trigger for fracture
healing defects, particularly atrophic nonunion. Clinical studies
over the past decade have revealed a threefold increase in the
nonunion rate in patients with ischemic injuries to tibia fracture
compared to average fracture patients.66 More importantly,
fracture nonunion can be signiﬁcantly improved by reconstruction
of the vascular structure and restoration of blood supply,67
suggesting the pivotal role of angiogenesis in the development of
fracture nonunion. Recent studies have indicated that chondrocytes and osteoblasts are two major cell sources that secrete
angiogenic factors to restore the blood supply via angiogenesis
during the initial fracture repair process. Restoration of the blood
supply then brings growth factors and oxygen to facilitate bony
callus formation through chondrogenic and osteogenic differentiation of progenitor cells and brings osteoclasts to remodel the
callus to regain the normal bone structure. Despite these ﬁndings,
the underlying mechanism by which impaired angiogenesis
results in atrophic nonunion, especially under pathological
inﬂammatory conditions, remains largely unknown. Therefore,
we comprehensively screened the angiogenic factors secreted
from chondrocytes and osteoblasts under IL-1β treatment.
Surprisingly, unlike chondrocytes, IL-1β induced the expression
of angiogenic factors in osteoblasts. In addition, IL-1β signiﬁcantly
induced VEGF expression in both chondrocytes and osteoblasts.
Several studies have demonstrated that VEGF and VEGF signaling
are a potent angiogenic factor and pathway, respectively, that
stimulate vessel formation and fracture repair in mice.57,68
However, our in vivo ﬁnding demonstrated that the RA mice
developed impaired angiogenesis due to inﬂammation, which led
us to speculate that the reduced angiogenic factors, but not VEGF,
are likely the direct downstream targets that mediate the reduced
angiogenesis observed in vivo. More importantly, SPP1 and
CXCL12 were identiﬁed as the two angiogenic factors reduced
to the greatest extent in IL-1β-treated chondrocytes. Their
physiologic importance was evident in HUVEC experiments that
showed that the addition of SPP1 and CXCL12 restored
angiogenic defects present in supernatants harvested from IL1b-treated chondrocyte cultures. These ﬁndings indicate that
chondrocytes are the target cells that mediate the angiogenic
defect observed in RA mice and that SPP1 and CXCL12 are
potential downstream targets of inﬂammation in chondrocytes.
However, our work does not completely dismiss the contribution
of osteoblasts and other angiogenic factors to angiogenesis and
atrophic nonunion.
This work uncovers several key ﬁndings that highlight its
important translational implication to treat atrophic nonunion.
Through the screening of angiogenic factors, in vitro angiogenesis
assays and a unique RA fracture nonunion model, we have
demonstrated that inﬂammation reduces the expression of SPP1
and CXCL12 in chondrocytes and leads to diminished angiogenesis and atrophic nonunion in mice. We also show that SPP1 and
CXCL12 are critical downstream targets of inﬂammation and that
supplementation with SPP1 and CXCL12 restored angiogenic
capacity in vitro. More importantly, controlled release of SPP1 and
CXCL12 locally via the PCL scaffold restored angiogenesis and
fracture repair in RA mice. Therefore, this work provides a
potential therapeutic approach to treat impaired angiogenesis
and fracture nonunion in patients, especially under inﬂammatory
conditions.
SPP1 and CXCL12 are chemokines demonstrated to stimulate
angiogenesis both during normal organ development and under
pathological conditions, such as various cancers. SPP1 itself can
recruit endothelial cells to form new blood vessels69 and can also
Bone Research (2021)9:29
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Fig. 6 The controlled release of SPP1 and CXCL12 restored angiogenesis and fracture nonunion in RA mice. a PCL scaffold with or without
SPP1 and CXCL12 was applied to the fractured bone in RA mice. b MicroCT assessment of newly formed vessels within fracture calluses from
RA mice treated with scaffolds with or without SPP1 and CXCL12 (n = 5) at 10 dpf. c Quantiﬁcation of the vessels in RA fracture calluses (n = 5)
at 10 dpf based on microCT assessment. The results were normalized to the scaffold only group. *P < 0.05 compared with control by Student’s
t-test. d Immunohistochemical staining for endomucin in fracture calluses from RA mice at 10 dpf. e Quantiﬁcation of the vessels in RA
fracture calluses at 10 dpf (n = 5) based on the immunohistochemical assessment. The results were normalized to the scaffold only group.
*P < 0.05 compared with control by Student’s t test. f Representative ABH/OG staining of fracture callus sections from RA mice treated with
scaffold with or without SPP1 and CXCL12 at 10 dpf (n = 5). g Histomorphometric quantiﬁcation of bone area was performed on 10 dpf
fracture callus sections from RA mice treated with scaffolds with or without SPP1 and CXCL12 (n = 5). The results were normalized to the
scaffold group. h Biomechanical torsion testing of RA fractures treated with scaffold with or without SPP1 and CXCL12 at 28 dpf (n = 8). Max
torque and displacement at max were quantiﬁed. All results were normalized to the controls. *P < 0.05 compared with control by Student’s
t test. Scale bar, 200 μm

attract macrophages and function synergistically with other
cytokines derived from macrophages to promote angiogenesis.70
Similarly, CXCL12 recruits CXCR4-positive endothelial cells and
facilitates angiogenesis.71 In regard to fracture healing, global
Bone Research (2021)9:29

knockout of either Spp150 or Cxcl1249 alone was shown to lead to
angiogenesis defects and impaired fracture healing in mice,
indicating the positive role of SPP1 and CXCL12 in angiogenesis
and fracture healing. Interestingly, there is increasing evidence that
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SPP1 and CXCL12 expression is upregulated in various tissues
under inﬂammatory conditions. Particularly in RA patients, high
concentrations of SPP1 and CXCL12 were detected in synovial
ﬂuid, and both SPP1 and CXCL12 were overexpressed in RA
synovial cells,72,73 which in turn led to excessive blood vessel
invasion and synovial joint destruction. However, in contrast to the
responses to inﬂammatory stimuli from synovial cells, SPP1 and
CXCL12 expression was speciﬁcally reduced in chondrocytes by IL1β. In accordance with these in vitro observations, the expression
of SPP1 and CXCL12 was also decreased in the callus in RA. These
ﬁndings highlight supplementation with SPP1 and CXCL12 as a
promising therapeutic approach to treat atrophic nonunion,
particularly chronic inﬂammation-induced nonunion.
Finally, as proof-of-concept experiment to show that the
administration of SPP1 and CXCL12 can restore angiogenesis
and is beneﬁcial for atrophic nonunion fracture healing, we
applied a PCL scaffold with SPP1 and CXCL12 to the fracture site in
RA mice. It is well established that excessive SPP1 and CXCL12 are
associated with cancer angiogenesis, metastasis, and malignancy.74,75 In addition, excessive angiogenesis mediated by SPP1
and CXCL12 in the synovium may exacerbate joint destruction in
RA patients. Therefore, to avoid potential side effects, we
engineered a PCL scaffold for the local sustained release of SPP1
and CXCL12 in the fracture site. The PCL scaffold is an FDAapproved biodegradable material that has been used for bone
regeneration in animals.76,77 The fabricated scaffolds are ﬁbrous,
mimicking the morphology of extracellular matrix in the
periosteum tissue. Notably, the scaffolds have a Young’s modulus
and tensile strength comparable to those of the periosteum
tissue.78 As expected, treatment with SPP1 or CXCL12 alone
showed beneﬁcial effects on angiogenesis and new bone
formation in the RA callus. More importantly, consistent with the
in vitro ﬁndings, the combination of SPP1 and CXCL12 exerted a
synergistic effect in vivo, i.e., signiﬁcantly induced angiogenesis to
a greater extent than either factor alone. Surprisingly, both factors
together also induced bony callus formation and fracture union at
10 dpf in the RA mice. While the individual delivery of SPP1 or
CXCL12 restored fracture repair in the RA mice with cartilage callus
and areas of new bone formation at 10 dpf fracture, the
combination treatment gave rise to a more mature bony callus
without residual cartilage, suggesting accelerated fracture healing.
This synergistic effect is likely due to the restoration of
endomucin-positive blood vessels by SPP1 and CXCL12, given
the evidence that endomucin-positive type H vessels are the most
important vessels for facilitating fracture callus ossiﬁcation and
union.79 In addition, SPP1 can signal through multiple integrins to
facilitate vessel formation through activation of the PI3K and MAP
kinase pathways in endothelial cells.80 Similarly, CXCL12 can also
activate the MAP kinase pathway through β-arrestin.81 Therefore,
it is reasonable to speculate that SPP1 and CXCL12 synergistically
induce angiogenesis in vitro and in vivo under inﬂammatory
conditions through the activation of MAP kinase pathways in
endothelial cells. Moreover, SPP1 is predominantly synthesized by
osteoblasts;43 therefore, it is possible that increased vessel
formation and bone formation are achieved through an SPP1mediated positive feedback loop. CXCL12 can also induce
osteoblast differentiation and mineralization,82,83 therefore accelerating bony callus formation in mice.
Overall, this work has high clinical relevance and signiﬁcant
translational potential. Our ﬁndings highlight the local delivery of
SPP1 and CXCL12 as an important therapeutic option to improve
angiogenesis and treat fracture atrophic nonunion, especially
under inﬂammatory conditions. In this regard, further optimizing
the release proﬁles of SPP1 and CXCL12 will be a focus of future
work. In addition, it will be valuable to clarify the mechanism by
which SPP1 and CXCL12 are affected by inﬂammation in a tissuespeciﬁc manner, particularly in chondrocytes under normal and
disease conditions. This will be achieved by using inducible Spp1

and Cxcl12 loss-of-function and gain-of-function mice as well as
“omics” high-throughput screening.
METHODS
Animals
All animal studies were performed in accordance with approval of
the Committees on Animal Resources at Washington University in
St Louis. Male C57BL/6J wild-type mice were purchased from The
Jackson Laboratory (#000664). Relb-Luc (NF-κB-GFP-Luciferase)
reporter mice84 were purchased from The Jackson Laboratory
(#027529) and used to visualize NF-κB activity in vivo. Systemic
inﬂammation was induced in 12-week-old mice via i.p. injection of
100 μL of arthritic K/BxN serum at day 0 and day 3 and maintained
by continuous injection every 5 d until the experimental endpoint.
Phosphate-buffered saline (PBS) was administered to mice as a
control. Bony fractures were generated on the right tibiae as
previously described.56
Bioluminescence imaging
PBS- and K/BxN serum-treated Relb-Luc reporter mice were given
150 mg·kg−1 luciferin and continuously monitored by an IVIS 50
imaging system (Xenogen/PerkinElmer) every 3 days for 15 days.
The luminescence intensity of the right hind legs was analyzed by
Living Image 3.0 software (Xenogen).
Histological analyses of fracture calluses
The fractured tibiae were collected for histological analyses at 7,
10, 14, and 21 dpf. Following 10% neutral buffered formalin
ﬁxation and decalciﬁcation by 14% ethylenediaminetetraacetic
acid, the fractured tibiae were embedded in parafﬁn, sectioned at
5 μm, and stained with Alcian blue/hematoxylin/orange G (ABH/
OG) and tartrate-resistant acid phosphatase (TRAP). The cartilage
and bone areas were measured using ImageJ software (Wayne
Rasband) based on ABH/OG staining. The osteoclast surface per
bone surface (Oc. S/BS) was measured and calculated based on
TRAP staining of 14 dpf fracture calluses. IHC staining for type III
collagen (1:500, Abcam, #ab7778), SPP1 (1:50, Abcam, #ab8448),
and CXCL12 (1:50, LSBio, #LS-B2437) was performed via
proteinase K antigen retrieval and DAB (3,3′-diaminobenzidine,
Vector Laboratories, #SK-4100)-mediated colorimetric development. Immunoﬂuorescence staining for endomucin (1:100, Santa
Cruz, #sc-65495) was performed via proteinase K antigen retrieval
and Alexa Fluor 488 antibody labeling kit (Thermo Fisher,
#A20181)-mediated ﬂuorescent development. Quantiﬁcation of
the vessel number was based on endomucin immunoﬂuorescence staining of the central fracture area (800 μm × 600 μm), and
the relative vessel count was calculated by normalization of the
experimental group to the control group.
MicroCT analyses
The fractured tibiae were collected at 10, 14, and 21 dpf and
examined by a microCT scanner (VivaCT 40, Scanco) with the
following parameters: 55 kV, 145 μA, and a 300 ms integration
time. 3D images were generated using Scanco software.
Quantiﬁcation of the BV and BV/TV was based on 600 slices
centered on the fracture site as previously described.56 Relative BV
and BV/TV were calculated by normalization of the experimental
group to the control group.
In vivo angiogenesis analysis
Each animal was perfused with Microﬁl MV-122 (Flowtech, #MV122), a lead chromate-based contrast agent, after which the
vascular structure surrounding the fracture site in the tibia was
examined by microCT with the following parameters: 55 kV,
145 μA, and a 300 ms integration time. 3D images were generated
using Scanco software. In this experiment, we analyzed the center
of the fracture area where the atrophic region was located and the
Bone Research (2021)9:29
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surrounding region. Quantiﬁcation of the vessel number was
based on 20 slices centered on the fracture site as previously
described.56 The relative vessel count was calculated by normalization of the experimental group to the control group.
Biomechanical torsion testing
The fractured tibiae were harvested at 28 dpf, and the ends were
secured with methacrylate (MMA) in 1.2-cm-long cylinders to
place the fracture site in the middle. The fracture tibiae were
tested in terms of torsion using a custom LabVIEW (National
Instruments) program until failure. The maximum torque and
displacement at maximum torque were recorded and processed
by a custom MATLAB 2017b program (Mathworks).
Primary chondrocyte isolation and culture
Primary chondrocytes were isolated from the ribcages of neonatal
C57BL/6J pups as previously described.56 Brieﬂy, the ribcages were
dissected without soft tissue, followed by 2 mg·mL−1 pronase
(Millipore Sigma, #10165921001) and 3 mg·mL−1 collagenase D
(Millipore Sigma, #11088866001) digestion with agitation. The
remaining sterna were further digested with 3 mg·mL−1 collagenase D for 4 to 6 h. Chondrocytes were collected and cultured in
DMEM with 10% FBS. Following 48 h of treatment with vehicle and
1 ng·mL−1 IL-1β, the culture medium was collected for the
angiogenic protein array and HUVEC angiogenesis assay.
Primary osteoblast isolation and culture
Primary osteoblasts were isolated from the calvarias of neonatal
C57BL/6J pups as previously described.85 Brieﬂy, after removing
the soft tissue and sutures, calvarias were digested with 0.1%
dispase (Millipore Sigma, #D4693) and 0.1% collagenase P
(Millipore Sigma, #11249002001). Osteoblasts released from the
mouse calvarias were collected and stimulated with 50 μg·mL−1
ascorbic acid (Millipore Sigma, #57803) for 3 days for maturation.
Following the treatment of mature osteoblasts with vehicle and
1 ng·mL−1 IL-1β for 48 h, the culture medium was collected for the
angiogenic protein array and HUVEC angiogenesis assay.
Angiogenic protein array
A Proteome Proﬁler Mouse Angiogenesis Array Kit (R&D, #ARY015)
was used to examine the expression of angiogenic factors in
medium collected from chondrocyte and osteoblast cultures
according to the manufacturer’s protocol. A Bio-Rad ChemiDoc
imaging system was used to visualize and quantify the array
signals.
In vitro angiogenesis assay
In the tube formation assay, 4 × 104 HUVECs were seeded and
cultured in 96-well plates precoated with Matrigel (Corning,
#356237) for 12 h. The numbers of formed tubes were examined
by ImageJ software. In the migration assay, medium collected
from chondrocyte cultures was added to the bottom chamber.
HUVECs (4 × 104) were seeded and cultured in the upper
chambers of a 24-well Transwell plate (Millipore Sigma,
#CLS3422) with serum-free medium for 12 h. Migrated HUVECs
were counted based on crystal violet staining. Then, 100 ng·mL−1
CXCL12 (Roche, #460-SD-010) and 500 ng·mL−1 SPP1 (Roche,
#441-OP-050) were individually added to chondrocyte culture
medium for HUVEC tube formation and migration assays. HUVEC
proliferation and apoptosis in culture medium from vehicle- and
IL-1β-treated chondrocytes were assessed with a Roche Cell
Proliferation ELISA Kit (Roche, #11647229001) and Cell Death
Detection ELISA Kit (Roche, #11774425001), respectively.
Fabrication of PCL scaffold with growth factors
The PCL scaffold was fabricated with PLGA microspheres containing SPP1 and CXCL12 via a coaxial electrospraying and electrospinning method as described previously.63 Brieﬂy, PCL (Millipore
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Sigma, #440744) was dissolved in chloroform (Millipore Sigma,
#372978) at a ﬁnal concentration of 5% and stored in syringe
pump A. A solution of 5% PLGA (Millipore Sigma, #P2191) was
dissolved in methylene chloride (Millipore Sigma, # M1550000)
and stored at syringe pump B. The growth factors 100 μg·mL−1
SPP1 (Peprotec, #120-35) and 20 μg·mL−1 CXCL12 (Peprotec, #30028B) were mixed with 0.5% gelatin (Millipore Sigma, #G6650) in
syringe pump C. PCL was injected at a rate of 5 mL·h−1 onto the
collecting mandrel 20 cm away. The PCL solution was charged at
+17 kV, while the collecting mandrel was charged at −10 kV. The
diameter of the collecting mandrel was 13 cm, and the rotation
rate was 800 r·min−1. The PLGA solution was sprayed at a rate of
1 mL·h−1 into the exterior aisle, and the solution containing
growth factors was simultaneously sprayed at a rate of 0.5 mL·h−1
into the interior aisle. The inner diameter of the coaxial apparatus
was 0.70 mm, and the outer diameter was 1.65 mm. The coaxial
aisle was charged at +20 kV, while the collecting mandrel was
charged at −10 kV. The distance between the electrospray needle
and collector was 30 cm. Four types of scaffolds were fabricated:
scaffolds with no growth factor, scaffolds with SPP1 alone,
scaffolds with CXCL12 alone, and scaffolds with both SPP1 and
CXCL12.
Scaffold characterization
We mixed a PLGA solution with 10 μg·mL−1 rhodamine B
(Millipore Sigma, #83689) and growth factor solution with
50 mg·mL−1 Hoechst (Millipore Sigma, #63493). The core–shell
structure was examined with a Zeiss LSM880 confocal microscope.
The scaffolds containing SPP1 and CXCL12 were sputter-coated
with gold. The ﬁber structure and microsphere distribution were
examined by SEM. The mechanical properties of the PCL scaffold
were examined by tensile testing. Brieﬂy, the PCL scaffold at a
150 μm thickness was cut into pieces 15 mm in length and 1 mm
in width. A 100 N load cell and tensile displacement rate of
0.5 mm·min−1 were applied to the scaffold. The force and
displacement were recorded. Tensile stress and strain were
calculated. The Young’s modulus was determined in the elastic
deformation region of the stress–strain curve.
Release proﬁles of growth factors from PCL scaffolds
PCL scaffolds (50 mg) containing growth factors (SPP1 and
CXCL12) were placed into 1 mL of PBS (HyClone, #SH30013.0.3)
supplemented with 1% penicillin and streptomycin (Thermo
Fisher, #15140122) and incubated at 37 °C for 4 weeks. The PBS
was collected at predetermined time points, and an equal volume
of fresh PBS was added. The collected PBS was used for ELISAs to
determine the concentrations of SPP1 and CXCL12 according to
the manufacturers’ protocol (R&D Systems, #DOST00 for SPP1;
Peprotec, #900-M92 for CXCL12).
In vitro bioactivity assay with PCL scaffolds
PCL scaffold was placed on the bottom of a 24-well plate. Five
hundred microliters of collagen gel (Corning, #354236) was cast
on the top of the scaffold, after which CM-Dil (Invitrogen, #C7000)labeled HUVECs were seeded at a density of 1 × 105 cells per mL.
After 5 days of culture, the constructs were ﬁxed with a 4%
paraformaldehyde solution (Thermo Fisher, #AAJ19943K2). The
cells were imaged with a confocal microscope. Z-stack images
were taken at a 20 µm thickness. HUVEC migration and lumen
formation were quantiﬁed based on the constructed 3D images.
Real-time qPCR
A 4 mm fracture callus was isolated from control and RA mice and
homogenized for RNA extraction using an RNeasy Mini Kit
(Qiagen, #74106). cDNA synthesis and real-time qPCR were
performed following the manufacturers’ protocol. The primer
sequences for Il1b, Il6, Il10, Tnfa, Spp1, Cxcl12, and Actb are
presented in Table 1.
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Table 1.

Primer sequences for qPCR

Gene

Sequences

Il1b

5′-GCA ACT GTT CCT GAA CTC AAC T-3′
5′-ATC TTT TGG GGT CCG TCA ACT-3′

Il6

5′-TCC AGT TGC CTT CTT GGG AC-3′
5′-GTA CTC CAG AAG ACC AGA GG-3′

Il10

5′-GCT CTT ACT GAC TGG CAT GAG-3′
5′-CGC AGC TCT AGG AGC TAG TG-3′

Tnfa

5′-CAC ACT CAG ATC ATC TTC TCA A-3′
5′-AGT AGA CAA GGT ACA ACC CAT C-3′

Spp1

5′-TCG TCA TCA TCG TCG TCC A-3′
5′-AGA ATG CTG TGT CCT CTG AAG-3′

Cxcl12

5′-GAC TCA CAC CTC TCA CAT CTT G-3′
5′-GTG CCC TTC AGA TTG TTG C-3′

Actb

5′-AGA TGT GGA TCA GCA AGC AG-3′
5′-GCG CAA GTT AGG TTT TGT CA-3′

Western blot analysis
Primary chondrocytes were seeded at a density of 1 × 106 cells per
well in a six-well plate and treated with vehicle, 20 ng·mL−1 IL-6 (R&D
Systems, #406-ML-005) and 20 ng·mL−1 TNFα (R&D Systems, #410MT-010) for 48 h. Cell lysates were separated by SDS-polyacrylamide
gel electrophoresis and examined with antibodies against the
following: SPP1 (1:1 000, Abcam, #ab8448), CXCL12 (1:1 000, LSBio,
#LS-B2437) and β-actin (1:4 000, Sigma, #2228).
Statistics
Statistical analyses were performed using GraphPad Prism. The
two-tailed Student’s t-test was used to determine the signiﬁcance
between two groups. Comparisons among multiple groups were
performed using two-way ANOVA followed by Tukey’s test. All
data are presented as the mean ± SD of at least three independent
experiments. P < 0.05 was used to indicate statistical signiﬁcance.
ACKNOWLEDGEMENTS
This work was supported by the following NIH/NIAMS grants: R01 grants (AR075860
and AR077616 to J.S., AR072623 and AR049192 to Y.A.; EB022018, HL138175,
HL138353, AG056919, and AR077616 to J.G.), an R21 grant (AR077226 to J.S.), a P30
Core Center grant (AR074992 to the Musculoskeletal Research Center), and a
biomedical grant from Shriners Hospital for Children (#85160 to Y.A.).

AUTHOR CONTRIBUTIONS
C.W. and X.N. participated in the experimental design. C.W., J.Y., X.N., T.Z., D.X., and G.S.
performed the experiments and data analysis. Y.A. provided arthritic K/BxN serum to
generate the RA mice. C.W., Y.A., J.G., and J.S. participated in manuscript writing and
revision. J.G. and J.S. planned the general outline of the project, guided the experimental
approach throughout the duration of the project, and ﬁnalized the manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41413-021-00150-4.
Competing interests: The authors declare no competing interests.

REFERENCES
1. Hadjiargyrou, M. & O’Keefe, R. J. The convergence of fracture repair and stem
cells: interplay of genes, aging, environmental factors and disease. J. Bone Min.
Res. 29, 2307–2322 (2014).
2. Einhorn, T. A. Enhancement of fracture-healing. J. Bone Jt. Surg. Am. 77, 940–956
(1995).
3. Megas, P. Classiﬁcation of non-union. Injury 36, S30–S37 (2005).

4. Stewart, S. K. Fracture non-union: a review of clinical challenges and future
research needs. Malays. Orthop. J. 13, 1–10 (2019).
5. Rupp, M. et al. Diaphyseal long bone nonunions—types, aetiology, economics,
and treatment recommendations. Int. Orthop. 42, 247–258 (2018).
6. Claes, L., Recknagel, S. & Ignatius, A. Fracture healing under healthy and
inﬂammatory conditions. Nat. Rev. Rheumatol. 8, 133–143 (2012).
7. Peel, N. F., Moore, D. J., Barrington, N. A., Bax, D. E. & Eastell, R. Risk of vertebral
fracture and relationship to bone mineral density in steroid treated rheumatoid
arthritis. Ann. Rheum. Dis. 54, 801–806 (1995).
8. Zura, R. et al. Epidemiology of fracture nonunion in 18 human bones. JAMA Surg.
151, e162775 (2016).
9. Deodhar, A. A. & Woolf, A. D. Bone mass measurement and bone metabolism in
rheumatoid arthritis: a review. Br. J. Rheumatol. 35, 309–322 (1996).
10. Hoes, J. N., Bultink, I. E. & Lems, W. F. Management of osteoporosis in rheumatoid
arthritis patients. Expert Opin. Pharmacother. 16, 559–571 (2015).
11. Manara, M. & Sinigaglia, L. Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open 1, e000065 (2015).
12. Xue, A. L. et al. Bone fracture risk in patients with rheumatoid arthritis: a metaanalysis. Medicine 96, e6983 (2017).
13. Inzana, J. A. et al. Bone fragility beyond strength and mineral density: Raman
spectroscopy predicts femoral fracture toughness in a murine model of rheumatoid arthritis. J. Biomech. 46, 723–730 (2013).
14. Okumura, G. et al. Experimental arthritis and Porphyromonas gingivalis administration synergistically decrease bone regeneration in femoral cortical defects. Sci.
Rep. 9, 20031 (2019).
15. Wellen, K. E. & Hotamisligil, G. S. Inﬂammation, stress, and diabetes. J. Clin.
Investig. 115, 1111–1119 (2005).
16. Baker, R. G., Hayden, M. S. & Ghosh, S. NF-kappaB, inﬂammation, and metabolic
disease. Cell Metab. 13, 11–22 (2011).
17. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inﬂammation and
metabolic disease. Nat. Rev. Immunol. 11, 85–97 (2011).
18. Hollinger, J. O., Schmitt, J. M., Hwang, K., Soleymani, P. & Buck, D. Impact of
nicotine on bone healing. J. Biomed. Mater. Res. 45, 294–301 (1999).
19. Brown, M. L. et al. Delayed fracture healing and increased callus adiposity in a
C57BL/6 J murine model of obesity-associated type 2 diabetes mellitus. PLoS ONE
9, e99656 (2014).
20. Lu, C. et al. Effect of age on vascularization during fracture repair. J. Orthop. Res.
26, 1384–1389 (2008).
21. Naik, A. A. et al. Reduced COX-2 expression in aged mice is associated with
impaired fracture healing. J. Bone Min. Res. 24, 251–264 (2009).
22. Lienau, J. et al. Differential regulation of blood vessel formation between standard and delayed bone healing. J. Orthop. Res. 27, 1133–1140 (2009).
23. Scott, D. L. & Kingsley, G. H. Tumor necrosis factor inhibitors for rheumatoid
arthritis. N. Engl. J. Med. 355, 704–712 (2006).
24. Khoury, M. et al. Inﬂammation-inducible anti-TNF gene expression mediated by
intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J.
Gene Med. 9, 596–604 (2007).
25. Choy, E. H., Kavanaugh, A. F. & Jones, S. A. The problem of choice: current biologic
agents and future prospects in RA. Nat. Rev. Rheumatol. 9, 154–163 (2013).
26. Furman, B. D. et al. Targeting pro-inﬂammatory cytokines following joint injury:
acute intra-articular inhibition of interleukin-1 following knee injury prevents
post-traumatic arthritis. Arthritis Res Ther. 16, R134 (2014).
27. Timmen, M. et al. Inﬂuence of antiTNF-alpha antibody treatment on fracture
healing under chronic inﬂammation. BMC Musculoskelet. Disord. 15, 184 (2014).
28. Beek, K. J. et al. Long-term treatment with TNF-alpha inhibitors improves bone
mineral density but not vertebral fracture progression in ankylosing spondylitis. J.
Bone Min. Res. 34, 1041–1048 (2019).
29. Deckers, M. M. et al. Expression of vascular endothelial growth factors and their
receptors during osteoblast differentiation. Endocrinology 141, 1667–1674 (2000).
30. Cackowski, F. C. et al. Osteoclasts are important for bone angiogenesis. Blood
115, 140–149 (2010).
31. Huang, B. et al. Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone. Nat.
Commun. 7, 13885 (2016).
32. Chen, J. L. et al. TGFbeta1 induces hypertrophic change and expression of
angiogenic factors in human chondrocytes. Oncotarget 8, 91316–91327 (2017).
33. Li, Z. et al. Angiogenic potential of human bone marrow-derived mesenchymal
stem cells in chondrocyte brick-enriched constructs promoted stable regeneration of craniofacial cartilage. Stem Cells Transl. Med. 6, 601–612 (2017).
34. Yuasa, M. et al. Fibrinolysis is essential for fracture repair and prevention of
heterotopic ossiﬁcation. J. Clin. Investig. 125, 3723 (2015).
35. Hausman, M. R., Schafﬂer, M. B. & Majeska, R. J. Prevention of fracture healing in
rats by an inhibitor of angiogenesis. Bone 29, 560–564 (2001).
36. Glowacki, J. Angiogenesis in fracture repair. Clin Orthop Relat Res, S82–S89 (1998).
37. Bell, A., Templeman, D. & Weinlein, J. C. Nonunion of the Femur and Tibia: an
update. Orthop. Clin. N. Am. 47, 365–375 (2016).

Bone Research (2021)9:29

The role of angiogenesis in fracture nonunion
C Wang et al.

13
38. Murnaghan, M., Li, G. & Marsh, D. R. Nonsteroidal anti-inﬂammatory drug-induced
fracture nonunion: an inhibition of angiogenesis. J. Bone Jt. Surg. Am. 88, 140–147
(2006).
39. Fassbender, M. et al. Local inhibition of angiogenesis results in an atrophic nonunion in a rat osteotomy model. Eur. Cell Mater. 22, 1–11 (2011).
40. Ding, Z. C., Lin, Y. K., Gan, Y. K. & Tang, T. T. Molecular pathogenesis of fracture
nonunion. J. Orthop. Transl. 14, 45–56 (2018).
41. Yamazaki, M. et al. Spatial and temporal distribution of CD44 and osteopontin in
fracture callus. J. Bone Jt. Surg. Br. 81, 508–515 (1999).
42. Hirakawa, K. et al. Localization of the mRNA for bone matrix proteins during
fracture healing as determined by in situ hybridization. J. Bone Min. Res. 9,
1551–1557 (1994).
43. Sodek, J. et al. Regulation of osteopontin expression in osteoblasts. Ann. N. Y.
Acad. Sci. 760, 223–241 (1995).
44. Morinobu, M. et al. Osteopontin expression in osteoblasts and osteocytes during
bone formation under mechanical stress in the calvarial suture in vivo. J. Bone
Min. Res. 18, 1706–1715 (2003).
45. Toupadakis, C. A. et al. Long-term administration of AMD3100, an antagonist of
SDF-1/CXCR4 signaling, alters fracture repair. J. Orthop. Res. 30, 1853–1859 (2012).
46. Murata, K. et al. Stromal cell-derived factor 1 regulates the actin organization of
chondrocytes and chondrocyte hypertrophy. PLoS ONE 7, e37163 (2012).
47. Jung, Y. et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible
mechanism for stem cell homing. Bone 38, 497–508 (2006).
48. Christopher, M. J., Liu, F., Hilton, M. J., Long, F. & Link, D. C. Suppression of CXCL12
production by bone marrow osteoblasts is a common and critical pathway for
cytokine-induced mobilization. Blood 114, 1331–1339 (2009).
49. Fujio, M. et al. Stromal cell-derived factor-1 enhances distraction osteogenesismediated skeletal tissue regeneration through the recruitment of endothelial
precursors. Bone 49, 693–700 (2011).
50. Duvall, C. L., Taylor, W. R., Weiss, D., Wojtowicz, A. M. & Guldberg, R. E. Impaired
angiogenesis, early callus formation, and late stage remodeling in fracture
healing of osteopontin-deﬁcient mice. J. Bone Min. Res. 22, 286–297 (2007).
51. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J.
Med. 365, 2205–2219 (2011).
52. Angelotti, F. et al. One year in review 2017: pathogenesis of rheumatoid arthritis.
Clin. Exp. Rheumatol. 35, 368–378 (2017).
53. Choy, E. Understanding the dynamics: pathways involved in the pathogenesis of
rheumatoid arthritis. Rheumatology 51, v3–v11 (2012).
54. Yamamoto, Y., Turkiewicz, A., Wingstrand, H. & Englund, M. Fragility fractures in
patients with rheumatoid arthritis and osteoarthritis compared with the general
population. J. Rheumatol. 42, 2055–2058 (2015).
55. Bastian, O. et al. Systemic inﬂammation and fracture healing. J. Leukoc. Biol. 89,
669–673 (2011).
56. Wang, C., Abu-Amer, Y., O’Keefe, R. J. & Shen, J. Loss of Dnmt3b in chondrocytes
leads to delayed endochondral ossiﬁcation and fracture repair. J. Bone Min. Res.
33, 283–297 (2018).
57. Buettmann, E. G. et al. VEGFA from early osteoblast lineage cells (Osterix+) is
required in mice for fracture healing. J. Bone Min. Res. 34, 1690–1706 (2019).
58. Hu, K. & Olsen, B. R. Osteoblast-derived VEGF regulates osteoblast differentiation
and bone formation during bone repair. J. Clin. Investig. 126, 509–526 (2016).
59. Pesesse, L. et al. Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis. Osteoarthr. Cartil. 21, 1913–1923 (2013).
60. Geris, L., Gerisch, A., Sloten, J. V., Weiner, R. & Oosterwyck, H. V. Angiogenesis in
bone fracture healing: a bioregulatory model. J. Theor. Biol. 251, 137–158 (2008).
61. Street, J. et al. Vascular endothelial growth factor stimulates bone repair by
promoting angiogenesis and bone turnover. Proc. Natl Acad. Sci. USA 99,
9656–9661 (2002).
62. Obayemi, J. D. et al. Degradable porous drug-loaded polymer scaffolds for
localized cancer drug delivery and breast cell/tissue growth. Mater. Sci. Eng. C.
Mater. Biol. Appl. 112, 110794 (2020).
63. Guo, X. et al. Creating 3D angiogenic growth factor gradients in ﬁbrous constructs to guide fast angiogenesis. Biomacromolecules 13, 3262–3271 (2012).
64. Mills, L. A. & Simpson, A. H. In vivo models of bone repair. J. Bone Jt. Surg. Br. 94,
865–874 (2012).
65. Garcia, P. et al. Development of a reliable non-union model in mice. J. Surg. Res.
147, 84–91 (2008).

Bone Research (2021)9:29

66. Dickson, K. F., Katzman, S. & Paiement, G. The importance of the blood supply in
the healing of tibial fractures. Contemp. Orthop. 30, 489–493 (1995).
67. Pretre, R., Peter, R. E. & Kursteiner, K. Limb revascularization to stimulate bone
fracture healing. Am. Surg. 63, 836–838 (1997).
68. Hu, K. & Olsen, B. R. The roles of vascular endothelial growth factor in bone repair
and regeneration. Bone 91, 30–38 (2016).
69. Wein, M. et al. Differential osteopontin expression in human osteoblasts derived
from iliac crest and alveolar bone and its role in early stages of angiogenesis. J.
Bone Min. Metab. 37, 105–117 (2019).
70. Rowe, G. C. et al. PGC-1alpha induces SPP1 to activate macrophages and orchestrate
functional angiogenesis in skeletal muscle. Circ. Res. 115, 504–517 (2014).
71. Liekens, S., Schols, D. & Hatse, S. CXCL12-CXCR4 axis in angiogenesis, metastasis
and stem cell mobilization. Curr. Pharm. Des. 16, 3903–3920 (2010).
72. Petrow, P. K. et al. Expression of osteopontin messenger RNA and protein in
rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from
articular chondrocytes and synovial ﬁbroblasts. Arthritis Rheum. 43, 1597–1605
(2000).
73. Kim, K. W. et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial ﬁbroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum. 56,
1076–1086 (2007).
74. Anborgh, P. H., Mutrie, J. C., Tuck, A. B. & Chambers, A. F. Role of the metastasispromoting protein osteopontin in the tumour microenvironment. J. Cell Mol. Med.
14, 2037–2044 (2010).
75. Sun, X. et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression.
Cancer Metastasis Rev. 29, 709–722 (2010).
76. Critchley, S. et al. 3D printing of ﬁbre-reinforced cartilaginous templates for the
regeneration of osteochondral defects. Acta Biomater. 113, 130–143 (2020).
77. Zhang, W. et al. 3D printed composite scaffolds with dual small molecule delivery
for mandibular bone regeneration. Biofabrication 12, 035020 (2020).
78. Uchiyama, E., Yamakoshi, K. & Sasaki, T. Measurement of mechanical characteristics of tibial periosteum and evaluation of local differences. J. Biomech. Eng. 120,
85–91 (1998).
79. Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and
osteogenesis by a speciﬁc vessel subtype in bone. Nature 507, 323–328 (2014).
80. Shevde, L. A. & Samant, R. S. Role of osteopontin in the pathophysiology of
cancer. Matrix Biol. 37, 131–141 (2014).
81. Guyon, A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front .Cell. Neurosci. 8, 65 (2014).
82. Tzeng, Y. S. et al. Imbalanced osteogenesis and adipogenesis in mice deﬁcient in
the chemokine Cxcl12/Sdf1 in the bone mesenchymal stem/progenitor cells. J.
Bone Min. Res. 33, 679–690 (2018).
83. Zhu, W., Liang, G., Huang, Z., Doty, S. B. & Boskey, A. L. Conditional inactivation of
the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to
impaired osteoblast development. J. Biol. Chem. 286, 26794–26805 (2011).
84. Everhart, M. B. et al. Duration and intensity of NF-kappaB activity determine the
severity of endotoxin-induced acute lung injury. J. Immunol. 176, 4995–5005 (2006).
85. Swarnkar, G., Zhang, K., Mbalaviele, G., Long, F. & Abu-Amer, Y. Constitutive
activation of IKK2/NF-kappaB impairs osteogenesis and skeletal development.
PLoS ONE 9, e91421 (2014).

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2021

